Suppressive therapy with valacyclovir in early genital herpes: A pilot study of clinical efficacy and herpes-related quality of life

Sexually Transmitted Diseases

Volumn 34, Issue 6, 2007, Pages 339-343

  Handsfield, H Hunter ^a,d   Warren, Terri ^b   Werner, Mica ^b   Phillips, James A ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Westover Heights Clinic   (United States)

^c Sage Statistical Solutions Inc   (United States)

^d BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VALACICLOVIR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EPIDEMIC; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; SCORING SYSTEM; STANDARD; TREATMENT DURATION; TREATMENT OUTCOME;

ACYCLOVIR; ADOLESCENT; ADULT; AMBULATORY CARE FACILITIES; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HERPES GENITALIS; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; MALE; OREGON; PILOT PROJECTS; QUALITY OF LIFE; RECURRENCE; TREATMENT OUTCOME; VALINE; WASHINGTON;

EID: 34249319131     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.olq.0000243620.13718.56     Document Type: Article

References (24)

1. Kimberlin DW, Rouse DJ. Genital herpes. N Engl J Med 2004; 350:1970 -1977.
2. Leone P, Fleming DT, Gilsenan AW, Li L, Justus S. Seroprevalence of herpes simplex virus-2 in suburban primary care offices in the United States. Sex Transm Dis 2004; 31:311-316.
3. Corey L, Handsfield H. Genital herpes and public health: addressing a global problem. JAMA 2000; 283:791-794.
4. Freeman EE, Weiss HS, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: Systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73-83.
5. Reitano M, Tyring S, Lang W, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: A large-scale dose range-finding study. J Infect Dis 1998; 178:603-610.
6. Diaz-Mitoma F, Sibbald RG, Shifran SD, Boon R, Saltzman RL. Oral famciclovir for the suppression of recurrent genital herpes: A randomized controlled trial. JAMA 1998; 280:887-892.
7. Goldberg LH, Kaufman R, Kurtz TO, et al. Long-term suppression of recurrent genital herpes with acyclovir: A 5-year benchmark. Arch Dermatol 1993; 129:582-587.
8. Patel R, Bodsworth NJ, Woolley P, et al. Valacyclovir for the suppression of recurrent genital HSV infection: A placebo controlled study of once daily therapy. Sex Transm Infect 1997; 73:105-109.
9. Sacks SL. Famciclovir suppression of asymptomatic and symptomatic recurrent anogenital herpes simplex virus shedding in women: A randomized, double-blind, double-dummy, place-controlled, parallel-group, single-center trial. J Infect Dis 2004; 189:1341-1347.
10. Gupta R, Wald A, Krantz E, et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis 2004; 190:1374-1381.
11. Wald A, Selke S, Warren T, et al. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex Transm Dis 2006; Epub ahead of print.
12. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004; 350:11-20.
13. Patel R, Tyring S, Strand A, Price MJ, Grant DM. Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection. Sex Transm Infect 1999; 75:398-402.
14. Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995; 333:770-775.
15. Gleaves C. Molecular detection of herpes simplex virus. Pan Am Soc Clin Virol 2006; 33:1-2.
16. Wald A, Morrow RA. Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection. Clin Infect Dis 2002; 35(suppl 2):S173-182.
17. Doward LC, McKenna SP, Kohlmann T, et al. The international development of the RGHQoL: A quality of life measure for recurrent genital herpes. Quality of Life Res 1998; 7:143-153.
18. Fisman DN. Health related quality of life in genital herpes: A pilot comparison of measures. Sex Transm Infect 2005; 81:267-270.
19. Fife KH, Almekinder J, Ofner S. A comparison of 1 year of episodic or suppressive treatment of recurrent genital herpes with valacyclovir. Sex Transm Dis. In press.
20. Engelberg R, Carrell D, Krantz E, Corey L, Wald A. Natural history of genital herpes simplex virus type 1 infection. Sex Transm Dis 2003; 30:174-177.
21. Patel R, Rompalo A. Managing patients with genital herpes and their sexual partners. Infect Dis Clin N Am 2005; 19:427-438.
22. Warren T, Ebel C. Counseling the patient who has genital herpes or genital human papillomavirus infection. Infect Dis Clin N Am 2005; 19:459-476.
23. Diamond C, Selke S, Ashley R, Benedetti J, Corey L. Clinical course of patients with serologic evidence of recurrent genital herpes presenting with signs and symptoms of first episode disease. Sex Transm Dis 1999; 26:221-225.
24. Wald A, Langenberg AG, Krantz E, et al. The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med 2005; 143:707-713.